The Catalyst



According to new research by Milliman, a leading actuarial consulting firm, only about 3.3 percent of Part D enrollees filled a prescription for at least one specialty drug in 2011, a very small portion of total Part D enrollme


In the future, we just might be able to control non-communicable diseases with our phones.

07.02.13 | By Preet Bilinski

We all know someone impacted by heart disease or stroke. Well that applies to the researchers working on medicines to combat these deadly diseases, as well. Not surprising when you consider that heart disease is the leading cause of death for both men and women, with someone dying from a heart disease related event every minute.


As we continue to explore health policy through our ‘Conversations’ forum, today we’re introducing the next question and encourage you to weigh in with your thoughts:

“Every day, thousands of Americans turn 65. How do we help ensure that the U.S. system is ready to meet their needs?

07.02.13 | By Sascha Haverfield, Ph.D.

As a recent update on implementation of the Prescription Drug User Fee Act (PDUFA) explained, a new review program for new molecular entity (NME) new drug applications (NDA) and original biologic license applications (BLA) was established under


CBS News featured a segment over the weekend on the value of new cancer treatments and how precision medicine, also known as personalized medicine, is changing the way patients receive care.

07.01.13 | By John Castellani

Last week, we introduced ‘Conversations,’ a new forum that provides experts, innovators, patients and other stakeholders an opportunity to share ideas through a live, ongoing dialogue about the future of health care.

07.01.13 | By John Castellani

We often discuss in the Catalyst the challenges and promise inherent in the drug discovery process and its impact on patients.